Work

Appropriate Use Criteria for Somatostatin Receptor PET Imaging in Neuroendocrine Tumors

Year: 2017

Type: article

Abstract: Somatostatin receptor (SSTR) PET has demonstrated a significant improvement over conventional imaging (CI) in patients with neuroendocrine tumors (NETs). SSTR PET should replace 111In-pentetreotide scintigraphy (OctreoScan; Mallinckrodt) in all indications in which the latter is currently being used

Source: Journal of Nuclear Medicine

DOI: 10.2967/jnumed.117.202275

Authors: Thomas A. Hope, Emily K. Bergsland, Murat Fani Bozkurt, Michael Graham, Anthony P. Heaney, Ken Herrmann, James R. Howe, Matthew H. Kulke, Pamela L. Kunz, Josh Mailman, Lawrence May, David C. Metz, Corina Millo, Sue O'Dorisio, Diane L. Reidy-Lagunes, Michael C. Soulen, Jonathan R. Strosberg

Institutions: American College of Radiology, Society of Nuclear Medicine and Molecular Imaging, American Society of Clinical Oncology, North American Neuroendocrine Tumor Society, European Association of Nuclear Medicine, Endocrine Society, Society of Surgical Oncology, National Comprehensive Cancer Network, American College of Physicians, American Gastroenterological Association

Language: English

Topic: Neuroendocrine Tumor Research Advances

Subfield: Epidemiology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: bronze

Funders: Society of Nuclear Medicine and Molecular Imaging, American Society of Clinical Oncology, University of Pennsylvania, Memorial Sloan-Kettering Cancer Center, Moffitt Cancer Center, National Comprehensive Cancer Network, Hacettepe Üniversitesi, National Institutes of Health, University of California, Los Angeles, University of California, San Francisco, National Cancer Institute

Award: G4062541594

OpenAlex ID: W2761539086

FWCI: 16.7

Cites: 85

Cited by: 363

Related to: 10